Objective:To explore the hemostatic mechanism of Jianpi Yiqi Shexue decoction(JYSD)by regulating vascular factors in an immune thrombocytopenia(ITP)mouse model.Methods:An ITP mouse model was established by the passive-immune modeling method,and inter-ventional drugs used were prednisone tablets and JYSD.The platelet count;vascular activity-related factors vWF,VCAM-1,and TM;and VEGF and bFGF were used as observational indicators.Results:On the 8th day of administration,compared with the model group,platelet counts in the prednisone and JYSD groups increased(both P＜.001).Compared with the control group,the levels of vWF,VCAM-1,and TM in the other groups were lower(all P＜.05).The VCAM-1 level in the JYSD group was higher than that in the prednisone group(P=.012),but without significant difference compared with the model group(P=.051).The TM level in the JYSD group was the lowest(vs.the model group,P=.047;vs.the prednisone group,P=.006).Compared with the control group,the IOD values of VEGF and bFGF in the other three groups were lower(all P＜.01).The IOD values of VEGF in the prednisone and JYSD groups were both higher than those in the model group(P=.002 and P＜.001,respectively).The IOD values of bFGF among the model,prednisone,and JYSD groups were not statistically significant(P＞.05).Conclusion:A vascular factor disorder is involved in the pathogenesis of ITP.JYSD can increase the platelet count,upregulate VEGF expression,and reduce the TM level.JYSD has the same effect as prednisone tablets in regulating platelet,vWF,VEGF,and bFGF,with a stronger effect in normalizing VCAM-1 and TM levels.The hemostatic mechanism of JYSD is closely related to the effective balance of vascular factors.

Objective:To explore changes in the serum TBNK lymphocyte subset levels in patients with lung cancer undergoing chemother-apy and analyze their correlation with prognosis.Methods:Ninety-two patients undergoing standard regimen lung cancer chemotherapy who attended Beijing Jingmei Group General Hospital from January 2020 to June 2023 were selected.The level of TBNK lymphocyte subpop-ulations was detected before the first chemotherapy and after one and three cycles of chemotherapy.Their prognosis was evaluated 3 months after the end of chemotherapy and assigned into the remission group(63 cases)and the non-remission group(29 cases).The correl-ation between the levels of TBNK lymphocyte subsets and prognosis was analyzed.Results:The CD3+,CD3+CD4+,and CD3-CD19+levels in the stage Ⅲ group were lower than those in the stage Ⅳ group after one and three cycles of chemotherapy,while the CD3+CD8+and CD3-CD16+CD56+levels were higher than those in the stage Ⅳ group(P<0.05).The CD3+,CD3+CD4+,and CD3-CD19+levels in the remission group were lower than those in the non-remission group after one and three cycles of chemotherapy,while the CD3+CD8+and CD3-CD16+CD56+levels were higher than those in the non-remission group(P<0.05).The staging and prognosis of lung cancer patients un-dergoing chemotherapy positively correlated with CD3+,CD3+CD4+,and CD3-CD19+,and negatively correlated with CD3+CD8+and CD3-CD16+CD56+(P<0.05).The area under the curve(AUC)of the TBNK lymphocyte subsets combined to predict the prognosis of lung can-cer patients after three cycles of chemotherapy was the highest,reaching 0.907(P<0.05).The TBNK lymphocyte subsets have a good risk warning effect on the prognosis of patients with lung cancer undergoing chemotherapy.Conclusions:Changes in peripheral blood TBNK lymphocyte subsets in patients with lung cancer undergoing chemotherapy were associated with immune function status and prognosis.Monitoring the levels of the relevant indicators can predict the prognosis of patients with lung cancer undergoing chemotherapy.